Key result
This review analyzes the diagnosis, risk stratification, and treatment of coronary heart disease in patients with end-stage renal disease, comparing revascularization and drug therapy.
Why the study?
To analyze the diagnosis and treatment of coronary heart disease in patients with end-stage renal disease based on current literature data.
This review summarizes current evidence on the diagnosis, risk stratification, and treatment (revascularization and medical therapy) of ischemic heart disease in patients with end-stage renal disease.
This review paper aims to analyze the problem of diagnosis and treatment of coronary heart disease (CHD), also called ischemic heart disease (IHD), in patients with end-stage renal disease (ESRD). The analysis is based on current literature data. The issues of CHD risk stratification before patient listing for kidney transplantation (KT) and possible difficulties of diagnosing CHD using non-invasive examination methods in ESRD patients are considered. The effectiveness of myocardial revascularization and drug therapy, endovascular and surgical myocardial revascularization, is compared. The paper also discusses the peculiarities of drug therapy, particularly antiplatelet and antihyperlipidemic therapy in the treatment of CHD in dialysis-dependent patients and kidney recipients.
No takes yet. Share an insight, caveat, or question.
Semenova et al. (2023) conducted a review in Ischemic heart disease in end-stage kidney disease. Myocardial revascularization and drug therapy was evaluated. This review analyzes the diagnosis, risk stratification, and treatment of coronary heart disease in patients with end-stage renal disease, comparing revascularization and drug therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: